<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606552</url>
  </required_header>
  <id_info>
    <org_study_id>1-2014-0074</org_study_id>
    <nct_id>NCT02606552</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparatively analyze the safety and validity of Amplazter Cardiac Plug (ACP) device-using&#xD;
      percutaneous left atrial appendage closure, and the medical treatment with dabigatran plus&#xD;
      aspirin or dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT&#xD;
      (dual-antiplatelet therapy)) in patient with coronary artery disease treated with&#xD;
      drug-eluting stent, accompanying atrial fibrillation.&#xD;
&#xD;
      Total of 670 patients [left atrial appendage occlusion registry with 100 ACP/ 570&#xD;
      anti-coagulation registry: (285 Dabigatran plus aspirin) and (285 Dabigatran plus&#xD;
      clopidogrel) therapy)] will be comparatively analyzed the safety and efficacy. Primary&#xD;
      endpoints were a composite of death, non-fatal myocardial infarction, stroke, systemic&#xD;
      embolism, and GUSTO bleeding (moderate to severe).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The number of patients registered for the study was low and it was expected to be difficult to&#xD;
    derive the study results.&#xD;
  </why_stopped>
  <start_date>July 20, 2016</start_date>
  <completion_date type="Actual">June 23, 2017</completion_date>
  <primary_completion_date type="Actual">June 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE (Major adverse cardiac and cerebrovascular events)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GUSTO bleeding</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of procedural related complications</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Dabigatran plus aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran plus clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplazter Cardiac Plug (ACP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatrain plus aspirin</intervention_name>
    <description>Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.</description>
    <arm_group_label>Dabigatran plus aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatrain plus clopidogrel</intervention_name>
    <description>Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.</description>
    <arm_group_label>Dabigatran plus clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplazter Cardiac Plug (ACP)</intervention_name>
    <description>Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).</description>
    <arm_group_label>Amplazter Cardiac Plug (ACP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients older than 20 years accompanying chronic atrial fibrillation with CHADS2&#xD;
             score ≥2&#xD;
&#xD;
          2. Patients with coronary artery disease (which requires DES) should receive the 2nd&#xD;
             generation drug-eluting stent insertion treatment&#xD;
&#xD;
          3. Subjects and their legal representatives must understand the main purpose of this&#xD;
             study, agree with relevant provisions, and sign to consent forms approved by IRBs of&#xD;
             each institution.&#xD;
&#xD;
          4. Subjects should agree with the follow-up studies as (coronary angiography) and&#xD;
             transesophageal echocardiography, etc.&#xD;
&#xD;
          5. Subjects should agree to follow our requests for post-operative follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients showing any hypersensitive reaction or reason for restriction to aspirin,&#xD;
             heparin, clopidogrel, or warfarin, or otherwise, susceptible to contrast media, and&#xD;
             therefore, who could not use those drugs and who were pregnant or breast feeding.&#xD;
&#xD;
          2. Comorbidities other than atrial fibrillation that required chronic warfarin use.&#xD;
&#xD;
          3. Patients diagnosed with progressive infection condition or endocarditis.&#xD;
&#xD;
          4. Patients who have been diagnosed with progressive gastric ulcer or upper&#xD;
             gastrointestinal bleeding for last 3 months.&#xD;
&#xD;
          5. Hemodynamically unstable patients who needs inotropic supports.&#xD;
&#xD;
          6. Senile dementia patients who have experienced any cerebrovascular accident (CVA) for&#xD;
             last 6 weeks.&#xD;
&#xD;
          7. Patients who have been diagnosed with intracardiac mass, thrombus, or vegetation as&#xD;
             echocardiographic findings.&#xD;
&#xD;
          8. Patients diagnosed with severe left ventricular dysfunction (&lt;LVEF 30%).&#xD;
&#xD;
          9. Patients with blood disorder as followings: leucopenia (&lt;WBC 3,000mm3), acute anemia&#xD;
             (&lt;Hg 9mg %), Thrombocytopenia (&lt;100,000 platelets/mm3), or any evidence of bleeding or&#xD;
             clotting disorders.&#xD;
&#xD;
         10. Patients showing life expectancy less than 12 months because of noncardiac&#xD;
             comorbidities.&#xD;
&#xD;
         11. Patients having severe vein occlusion at femoral vein, ceiling vein, or inferior vena&#xD;
             cava.&#xD;
&#xD;
         12. A patent foramen ovale with atrial septal aneurysm and right-to-left shunt&#xD;
&#xD;
         13. Symptomatic carotid artery disease&#xD;
&#xD;
         14. Patients with severe valvular heart disease&#xD;
&#xD;
         15. Patients who are currently participating in other clinical trials for any drug or&#xD;
             medical device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting stent</keyword>
  <keyword>atrial appendage closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

